Detailed financial statements for Halozyme Therapeutics, Inc. (HALO): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20).
Analysis Summary
Halozyme Therapeutics, Inc. reported revenue of $1.40B in the most recent fiscal year, growing at a 5-year CAGR of 39.2%. Net income reached $316.9M, with a 19.7% 5-year CAGR.
Trailing-twelve-month margins: gross margin 78.2%, operating margin 56.8%, net margin 24.9%. Free cash flow grew at 64.8% CAGR over 5 years.
Balance sheet quality for HALO: current ratio of 4.7, net debt of $2.00B. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is strong: free cash flow of $644.6M represents 203% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $146.7M | $316.6M | $151.9M | $196.0M | $267.6M | $443.3M | $660.1M | $829.3M | $1.02B | $1.40B |
| Cost of Revenue | $33.2M | $31.2M | $10.1M | $45.5M | $43.4M | $81.4M | $139.3M | $192.4M | $159.4M | $305.4M |
| Gross Profit | $113.5M | $285.5M | $141.7M | $150.4M | $224.2M | $361.9M | $520.8M | $636.9M | $855.9M | $1.09B |
| Research & Development | $150.8M | $150.6M | $150.3M | $140.8M | $34.2M | $35.7M | $66.6M | $76.4M | $79.0M | $81.5M |
| Selling, General & Admin | $45.9M | $53.8M | $60.8M | $77.3M | $45.7M | $50.3M | $143.5M | $149.2M | $154.3M | $193.4M |
| Operating Expenses | $196.7M | $204.5M | $211.1M | $218.1M | $80.0M | $86.0M | $253.3M | $299.3M | $304.4M | $274.9M |
| Operating Income | -$83.2M | $81.0M | -$69.3M | -$67.6M | $144.3M | $275.9M | $267.5M | $337.6M | $551.5M | $816.3M |
| EBITDA | -$79.5M | $83.2M | -$69.3M | -$56.6M | $153.0M | $259.0M | $315.5M | $451.9M | $656.5M | $573.1M |
| Interest Expense | $20.0M | $22.0M | $18.0M | $11.6M | $20.4M | $7.5M | $16.9M | $18.8M | $18.1M | $18.1M |
| Pre-tax Income | -$101.9M | $61.6M | -$79.8M | -$72.3M | $129.3M | $248.5M | $248.9M | $348.3M | $557.1M | $466.9M |
| Income Tax | $1.2M | -$1.4M | $537000 | -$11000 | $217000 | -$154.2M | $46.8M | $66.7M | $113.0M | $150.0M |
| Net Income | -$103.0M | $63.0M | -$80.3M | -$72.2M | $129.1M | $402.7M | $202.1M | $281.6M | $444.1M | $316.9M |
| EPS | $-0.81 | $0.46 | $-0.56 | $-0.50 | $0.95 | $2.86 | $1.48 | $2.13 | $3.50 | $2.64 |
| EPS (Diluted) | $-0.81 | $0.45 | $-0.56 | $-0.50 | $0.91 | $2.74 | $1.44 | $2.10 | $3.43 | $2.56 |
| Shares Outstanding (Diluted) | $128.0M | $139.1M | $143.6M | $144.3M | $141.5M | $146.8M | $140.6M | $134.2M | $129.4M | $123.9M |
Income Statement (Quarterly)
| Year | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|---|---|---|---|
| Revenue | $354.3M | $451.8M | $376.7M | $481.0M |
| Gross Profit | $281.3M | $349.6M | $268.0M | $401.8M |
| Operating Income | $217.9M | $254.4M | $184.5M | $287.7M |
| EBITDA | $243.7M | -$69.3M | $219.6M | $320.0M |
| Net Income | $175.2M | -$141.6M | $150.0M | $229.9M |
| EPS | $1.49 | $-1.20 | $1.27 | $1.96 |
| EPS (Diluted) | $1.43 | $-1.20 | $1.22 | $1.90 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $66.8M | $168.7M | $57.9M | $120.2M | $147.7M | $118.7M | $234.2M | $118.4M | $115.8M | $133.8M |
| Short-term Investments | $138.2M | $300.5M | $296.6M | $301.1M | $220.3M | $622.2M | $128.6M | $217.6M | $480.2M | $9.0M |
| Receivables | $15.7M | $22.1M | $30.0M | $59.4M | $97.7M | $91.0M | $231.1M | $234.2M | $308.5M | $441.3M |
| Inventory | $14.6M | $5.1M | $22.6M | $29.4M | $60.7M | $53.9M | $100.1M | $127.6M | $141.9M | $176.5M |
| Total Current Assets | $256.5M | $510.4M | $427.8M | $543.4M | $554.8M | $926.3M | $739.0M | $746.4M | $1.09B | $825.2M |
| Property, Plant & Equipment | $4.3M | $3.5M | $7.5M | $10.9M | $10.6M | $8.8M | $75.6M | $74.9M | $75.0M | $82.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | $409.0M | $416.8M | $416.8M | $580.4M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | $546.7M | $472.9M | $401.8M | $981.5M |
| Total Assets | $261.5M | $519.9M | $440.2M | $565.9M | $579.9M | $1.10B | $1.84B | $1.73B | $2.06B | $2.53B |
| Accounts Payable | $3.6M | $7.9M | $4.1M | $6.4M | $1.9M | $1.5M | $17.7M | $11.8M | $10.2M | $20.9M |
| Short-term Debt | $17.4M | $77.2M | $91.5M | $19.5M | $397.2M | $89.4M | $13.3M | 0 | 0 | 0 |
| Total Current Liabilities | $54.6M | $131.3M | $149.4M | $85.6M | $421.4M | $117.1M | $130.8M | $112.5M | $139.1M | $177.1M |
| Long-term Debt | $199.2M | $125.1M | $34.9M | $383.0M | 0 | $787.3M | $1.49B | $1.50B | $1.51B | $2.14B |
| Total Liabilities | $294.0M | $311.6M | $191.4M | $474.1M | $428.9M | $907.5M | $1.67B | $1.65B | $1.70B | $2.48B |
| Retained Earnings | -$585.3M | -$522.4M | -$531.4M | -$603.7M | -$474.6M | -$58.9M | $143.2M | $90.5M | $359.9M | $54.8M |
| Total Equity | -$32.5M | $208.4M | $248.9M | $91.8M | $151.0M | $197.0M | $169.8M | $83.8M | $363.8M | $48.8M |
| Total Debt | $216.6M | $202.4M | $126.4M | $402.6M | $397.2M | $876.7M | $1.51B | $1.50B | $1.51B | $2.14B |
| Net Debt | $11.6M | -$266.9M | -$228.1M | -$18.7M | $29.2M | $135.8M | $1.14B | $1.16B | $909.7M | $2.00B |
| Working Capital | $201.9M | $379.0M | $278.5M | $457.8M | $133.4M | $809.1M | $608.2M | $633.9M | $946.2M | $648.1M |
Balance Sheet (Quarterly)
| Year | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|---|---|---|---|
| Cash & Equivalents | $419.7M | $133.8M | $309.7M | $163.1M |
| Total Assets | $2.22B | $2.53B | $2.67B | $2.58B |
| Total Liabilities | $1.72B | $2.48B | $2.45B | $2.43B |
| Total Equity | $503.9M | $48.8M | $219.6M | $143.5M |
| Total Debt | $1.51B | $2.14B | $2.14B | $2.15B |
Cash Flow (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$103.0M | $63.0M | -$80.3M | -$72.2M | $129.1M | $402.7M | $202.1M | $281.6M | $444.1M | $316.9M |
| Depreciation & Amortization | $2.4M | $2.2M | $2.4M | $6.6M | $17.4M | $6.6M | $57.5M | $84.9M | $88.7M | $88.1M |
| Stock-based Compensation | $25.6M | $30.7M | $35.7M | $34.8M | $17.2M | $20.8M | $24.4M | $36.6M | $43.4M | $51.6M |
| Change in Working Capital | $17.0M | $20.7M | -$5.9M | -$55.2M | -$67.2M | $2.6M | -$110.5M | -$38.7M | -$136.3M | -$152.3M |
| Operating Cash Flow | -$50.4M | $134.1M | -$49.5M | -$85.4M | $55.5M | $299.4M | $240.1M | $388.6M | $479.1M | $651.6M |
| Capital Expenditure | -$3.1M | -$1.4M | -$4.7M | -$4.0M | -$2.5M | -$1.5M | -$4.8M | -$15.3M | -$10.7M | -$7.0M |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | -$999.1M | 0 | 0 | -$726.0M |
| Stock Repurchased | 0 | 0 | 0 | -$200.0M | -$150.1M | -$350.1M | -$200.0M | -$402.4M | -$250.0M | -$342.4M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -$53.5M | $132.7M | -$54.2M | -$89.5M | $53.0M | $298.0M | $235.3M | $373.3M | $468.4M | $644.6M |
Cash Flow (Quarterly)
| Year | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|---|---|---|---|
| Operating Cash Flow | $178.6M | $219.0M | $180.1M | $240.9M |
| Capital Expenditure | -$3.0M | -$1.4M | -$3.7M | -$4.2M |
| Free Cash Flow | $175.6M | $217.6M | $176.3M | $236.7M |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Stock-based Compensation | $12.2M | $16.6M | $16.6M | $17.7M |
Growth & Margins (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth (YoY) | +115.8% | -52.0% | +29.1% | +36.5% | +65.7% | +48.9% | +25.6% | +22.4% | +37.6% | |
| Net Income Growth (YoY) | +161.1% | -227.6% | +10.1% | +278.7% | +212.0% | -49.8% | +39.3% | +57.7% | -28.6% | |
| EPS Growth (YoY) | +156.8% | -221.7% | +10.7% | +290.0% | +201.1% | -48.3% | +43.9% | +64.3% | -24.6% | |
| Shares Change (YoY) | +8.7% | +3.3% | +0.5% | -2.0% | +3.8% | -4.2% | -4.6% | -3.6% | -4.3% | |
| FCF Growth (YoY) | +348.0% | -140.8% | -65.2% | +159.2% | +462.8% | -21.0% | +58.6% | +25.5% | +37.6% | |
| Gross Margin | 77.4% | 90.2% | 93.3% | 76.8% | 83.8% | 81.6% | 78.9% | 76.8% | 84.3% | 78.1% |
| Operating Margin | -56.7% | 25.6% | -45.7% | -34.5% | 53.9% | 62.2% | 40.5% | 40.7% | 54.3% | 58.4% |
| EBITDA Margin | -54.2% | 26.3% | -45.7% | -28.9% | 57.2% | 58.4% | 47.8% | 54.5% | 64.7% | 41.0% |
| Net Margin | -70.2% | 19.9% | -52.9% | -36.9% | 48.2% | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% |
| FCF Margin | -36.5% | 41.9% | -35.7% | -45.6% | 19.8% | 67.2% | 35.6% | 45.0% | 46.1% | 46.2% |
| Effective Tax Rate | -1.1% | -2.2% | -0.7% | 0.0% | 0.2% | -62.0% | 18.8% | 19.2% | 20.3% | 32.1% |
Per-Share Data (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF Per Share | $-0.42 | $0.95 | $-0.38 | $-0.62 | $0.37 | $2.03 | $1.67 | $2.78 | $3.62 | $5.20 |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | $127.2M | $136.4M | $143.4M | $144.3M | $136.2M | $140.6M | $136.8M | $131.9M | $126.8M | $119.8M |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Profitability
| Gross Margin | 78.18% |
| Operating Margin | 56.77% |
| Net Margin | 24.86% |
Financial Health
| Debt / Equity | 14.95 |
| Current Ratio | 2.71 |
Key Ratios (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | -12.20 | 44.04 | -26.12 | -35.46 | 44.96 | 14.06 | 38.45 | 17.35 | 13.66 | 25.49 |
| P/B | -38.69 | 13.26 | 8.43 | 27.89 | 38.51 | 28.71 | 45.86 | 58.18 | 16.67 | 165.22 |
| P/S | 8.57 | 8.73 | 13.82 | 13.06 | 21.74 | 12.76 | 11.80 | 5.88 | 5.97 | 5.77 |
| Gross Margin | 77.4% | 90.2% | 93.3% | 76.8% | 83.8% | 81.6% | 78.9% | 76.8% | 84.3% | 78.1% |
| Operating Margin | -56.7% | 25.6% | -45.7% | -34.5% | 53.9% | 62.2% | 40.5% | 40.7% | 54.3% | 58.4% |
| Net Margin | -70.2% | 19.9% | -52.9% | -36.9% | 48.2% | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% |
Related companies: ABVX · ATR · CAI · CORT · CYTK · GRFS · HSIC
Explore sector: Healthcare · Biotechnology
More sections of HALO: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks